Peak BggrAmgen Amgen: One Of The Few Bargains In This Market (NASDAQ:AMGN) verified_publisherSeeking Alpha Amgen seems to be undervalued at this point if we assume that Amgen can grow in the low-to-mid single digits.
Peak BggrInvesting Apellis Pharma halts Phase 1/2 trial for APL-9 in severe COVID-19 verified_publisherSeeking Alpha - Dulan Lokuwithana, SA News Editor Apellis Pharma halts Phase 1/2 trial for APL-9 in severe COVID-19 Apellis Pharmaceuticals (NASDAQ:APLS) announced that it would no longer pursue the …
Peak BggrInvesting Editas Medicine CEO buys company shares on the dip verified_publisherSeeking Alpha - Dulan Lokuwithana, SA News Editor Editas Medicine (NASDAQ:EDIT) has surged ~2.5% in the post-market after its CEO James Mullen disclosed the purchase of 25K of company shares at …
Peak BggrInvesting Passage Bio (PASG) Stock - An In-depth Analysis verified_publisherSeeking Alpha Passage Bio has few drug candidates in its pipeline including three that should begin Phase 1/2 studies soon. Merits a small "watch item" position …
Peak BggrCancer Circling Back On Oncocyte Stock (NYSEMKT:OCX) verified_publisherSeeking Alpha This small cancer diagnostic firm is in the early stages of its commercialization efforts and just made a small, strategic "bolt-on" acquisition.
